Transparency Market Research
Prostate Health Market Surges Towards USD 83.8 Billion by 2034, Fueled by Advancements in Diagnostic and Treatment Technologies | TMR Report
July 08, 2024 09:58 ET | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research. Inc. , July 08, 2024 (GLOBE NEWSWIRE) -- The prostate health market (Markt für Prostatagesundheit) was projected to attain US$ 31.9...
Lantheus Acquires Global Rights to Life Molecular Imaging’s Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers
June 27, 2024 07:05 ET | Lantheus Holdings, Inc.
BEDFORD, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...
Curium gibt erste kommerzielle Dosen von PYLCLARI® - 18F-PSMA PET radiopharmazeutikum in Österreich bekannt
June 17, 2024 08:51 ET | Curium
Erste Dosen von PYLCLARI® werden Anfang Mai 2024 in Österreich verabreichtPYLCLARI® jetzt auch in Frankreich, Deutschland, Griechenland, Italien und den Niederlanden erhältlich PARIS, June 17, 2024 ...
Curium Continues to Make Strong Progress in European Roll-Out Of PYLCLARI® – 18F-PSMA PET Diagnostics of Patients With Prostate Cancer
June 17, 2024 08:51 ET | Curium
First doses of PYLCLARI® administered in Austria in early May 2024PYLCLARI® now available in France, Germany, Greece, Italy, and the Netherlands PARIS, June 17, 2024 (GLOBE NEWSWIRE) -- Curium, a...
Curium Extends Irradiation Partnership With NRG I PALLAS in Netherlands for Continuous Supply of Lutetium-177 to Treat 1,000s of Cancer Patients Each Year
May 29, 2024 03:32 ET | Curium
PARIS, May 29, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that it has signed a long-term agreement to extend its current partnership with NRG I PALLAS for...
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
May 23, 2024 17:00 ET | Arvinas Inc.
NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2...
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
May 16, 2024 06:00 ET | Arvinas Inc.
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in...
Global Precision Oncology Market
$163 Billion Precision Oncology Markets - Global Industry Size, Share, Trends, Opportunity & Forecast, 2019-2023 & 2024-2029F
May 14, 2024 02:52 ET | Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Precision Oncology Market - Global Industry Size, Share, Trends, Opportunity & Forecast, 2019-2029F" report has been added to ...
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
May 09, 2024 16:42 ET | Arvinas Inc.
NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the...